Adjuvant therapy with recombinant interferon-gamma (rIFN-γ) has shown to be effective in BCG-osis associated with some types of MSMD and chronic granulomatous disease (CGD) [9, 10]. The gene discussed is IFNG; the disease is Mendelian susceptibility to mycobacterial diseases.